EastGate Biotech Attends Arab Health Conference Seeking Additional Joint Venture Partnerships

e both our JV partner and Bill represent Eastgate at the conference,” said Anna Gluskin CEO of Eastgate Biotech.  “Not only can they spread the word of a paradigm changing the way to treat the diabetes epidemic, but they can sit down with decision makers and set the framework for future collaborations.  We are looking for additional joint venture deals and collaborations.  Our approach is to license the world piece by piece.  Bill has a gift of going to these shows and getting people very excited about our technology and has always come back with great leads and in some cases licensing agreements.  The show appears to be going quite well and we hope this translates into more Joint Venture partnerships in the near future.  I am very proud of the team we have been able to cultivate at Eastgate.”


About Arab Health

Arab Health prides itself as the leading healthcare business platform in the Middle East. Connecting manufacturers and service providers with clinicians, procurement professionals, dealers, and distributors is the primary goal of the event. Leverage the success of the show and make key business contacts by utilizing our multiple channels to connect you to the region’s healthcare industry. For 44 years Arab Health has brought you the latest innovations in healthcare. From state-of-the-art imaging equipment to the most cost-effective disposables; developments in surgery to advances in prosthetics, Arab Health continues to be at the heart of healthcare in the Middle East. As the largest collection of healthcare product manufacturers and service providers under one roof, Arab Health is your one-stop shop for all your healthcare sourcing and procurement needs. With thousands of products to explore, coming in from more than 68 countries, make sure you don’t miss this essential business event. The show is free to visit.


About Eastgate Biotech

Eastgate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increases the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. Eastgate’s wholly owned subsidiary Omni Surgery and Anti-Aging Centre are the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.


About Netris / Origin Biopharmaceutical

Netris / Origin Biopharmaceutical has been registered with the Pakistan Ministry of Health since 2002 and is licensed for distribution, marketing, importing and supplying the Government with therapeutic drugs. Netris Bio looks to capitalize on cutting edge technologies and take advantage of emerging trends in the pharmaceutical industry to quickly and safely bring drugs to the Pakistan market. Netris Bio has a team of 167 highly dedicated professionals that allow the company to get more done with less to its highly collaborative work environment that resembles more of a big family than a biotech company. The company currently markets Citicoline injections, Pantoprazole infusions, omeprazole, heparin, enoxaparin, cephalosporin, anti-cancer, and cardiac. In addition, the company collects blood plasma and markets biologics, vaccines, nutraceuticals, and Neuro products.



Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbor” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates, and projections as of the date of this news release.

The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models, and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by Eastgate with the SEC, which should be considered together with any forward-looking statement. Eastgate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



Rose Perri


Email: information@eastgatepharmaceuticals.com

Website: www.EastGateBiotech.com

SOURCE: Eastgate Biotech Corp.

Leave a Reply

Your email address will not be published. Required fields are marked *